Italy's Chiesi buys Zymenex for rare genetic disease work; Analysts forecast blockbuster sale for Roche schizophrenia drug;

@FierceBiotech: Syndax snags $26.6M round for Phase III breast cancer study. More | Follow @FierceBiotech

@JohnCFierce: Patient advocacy or Amgen's blockbuster protection act? Biosimilars bills advance. Report | Follow @JohnCFierce

> Italy's Chiesi Group is acquiring Zymenex, a UK group focused on developing new therapies for rare genetic diseases. Release

> Decision Resources says that Roche/Chugai's schizophrenia drug bitopertin should go on to earn $1.5 billion after a launch in 2016. Story

Medical Device News

@FierceMedDev: Sign up for our new publication, FierceDiagnostics, launching with its first weekly newsletter tomorrow. Sign up here | Follow @FierceMedDev

@DamianFierce: Covidien has opened the doors of a new $21M South Korean R&D shop. More | Follow @DamianFierce

@MarkHFierce: Edwards, fresh from a patent lawsuit victory, is heralding a German injunction on Medtronic CoreValve sales. Story | Follow @MarkHFierce

@MichaelGFierce: Ceptaris nets first-ever FDA approval for topical lymphoma chemo gel. More from FierceDrugDelivery | Follow @MichaelGFierce

> Covidien cuts ribbon on $21M Korean R&D shop. Report

> New sleep apnea treatment devices emerge. Story

> LDR files for $69M IPO following FDA approval. Article

> Volcano buying Medtronic's imaging catheter. News

> Vestagen pulls in $8.25 million for high-tech medical scrub uniforms. Item

Pharma News

@FiercePharma: Sudden CFO departure at Actelion, just as Swiss drug maker wraps up Ceptaris buyout. More | Follow @FiercePharma

@EricPFierce: Swiss CMO Siefried building a manufacturing plant in China. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: From FierceVaccines: Low vaccination rate at megachurch linked to measles outbreak. Story Follow @CarlyHFierce

> China arrests British couple for trafficking in private information. News

> Bayer's Nexavar in FDA fast lane for thyroid cancer use. Report

> Akorn buys rival Hi-Tech for $640M. Article

> Lonza will cut 200 at Massachusetts plant by end of year. Story

Biotech Research News

@EmilyMFierce: Omega-3 alleviates ADHD symptoms in rats. More | Follow @EmilyMFierce

> High copper levels implicated in Alzheimer's disease. Story

> Single injection could provide new treatment for melanoma. Article

> New target to battle Parkinson's discovered. News

> Gene therapy in mice improves Rett syndrome. More

> Sodium 'switch' could provide target to treat brain disorders. Item

Pharma Manufacturing News

> Akorn buys Hi-Tech for $640M to tap manufacturing expertise. Report

> Amarin asks FDA to approve Novasep as Vascepa partner. Story

> Lonza starting job cuts at troubled U.S. biologics plant. Article

> Ontario helps Pillar5 expand plant. Item

> Another Fresenius plant in FDA crosshairs. More

And Finally… Researchers at the Salk Institute in La Jolla, CA, say that a molecule that blocks light sensors in the eye could be effective in treating migraines. Release